Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score
Curative treatment of pseudomyxoma peritonei (PMP) is complete cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC).
The aim of this study was to build and evaluate a preoperative imaging score to predict resectability.
Patients and methods
Between 2007 and 2014, all PMP patients in two tertiary reference centers who underwent laparotomy with intent to undergo CRS and HIPEC were included in this study retrospectively. Thickness of tumor burden was measured on preoperative multidetector-row computed tomography (MDCT) by two radiologists blinded to surgical results in five predetermined areas. Patients were divided into two cohorts with the same resectability rate (building and validation). The performances of the scores were assessed using receiver operating characteristic (ROC) curve analyses.
Overall, 126 patients were included, with compete CRS being achieved in 91/126 patients (72.2%). Two cohorts of 63 patients matched by age, sex, burden of disease, resectability rate, and pathological grade were constituted. The MDCT score was the sum of the five measures, and was higher in unresectable disease [median 46.2 mm (range 27.9–74.6) vs. 0.0 mm (range 0.0–14.0), p < 0.001]. Area under the ROC curve was 0.863 (range 0.727–0.968) and 0.801 (range 0.676–0.914) in the building and validation cohorts, respectively. A threshold of 28 mm yielded a sensitivity, specificity, positive predictive and negative predictive value of 94, 81, 81 and 94% in the building cohort, and 80, 68, 59 and 85% in the validation cohort, respectively. Using our score, overall and disease-free survival were increased in the group classified as resectable.
A simple preoperative MDCT score measuring tumor burden in the perihepatic region is able to predict resectability and survival of PMP patients.
Morgane Bouquot, Anthony Dohan, Etienne Gayat, Maxime Barat, Olivier Glehen, Marc Pocard, Pascal Rousset, and Clarisse Eveno have no financial or other personal conflicts of interest to declare.
Morgane Bouquot contributed to the acquisition of data, writing of the manuscript and analysis of data. Anthony Dohan, Maxime Barat and Clarisse Eveno contributed to development of the methodology, interpretation of data, and conception, design, and review of the manuscript. Etienne Gayat contributed to development of the methodology, analysis and interpretation of data, and writing and review of the manuscript. Olivier Glehen and Marc Pocard contributed to revision of the manuscript and study supervision. Pascal Rousset contributed to acquisition and analysis of data, and review of the manuscript.
- 3.Slim K, Blay JY, Brouquet A, et al. Digestive oncology: surgical practices [in French]. J Chir (Paris). 2009;146(Suppl 2):S11–S80.Google Scholar
- 15.Chua TC, Al-Zahrani A, Saxena A, et al. Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2011;18(6):1582–89.CrossRefPubMedGoogle Scholar
- 33.Pocard M, Eveno C, Valleur P. Regarding “two steps procedure for pseudomyxoma”. Ann Surg Oncol. 2011;18(1):282–83; author reply 284–85.Google Scholar